Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vericel (VCEL) Acquisitions (2014 - 2019)

Vericel recorded quarterly Acquisitions of $13.9 million in Q3 2019, down 35.99% quarter-over-quarter from $21.7 million in Q2 2019, and down 68.75% year-over-year from $44.5 million in Q3 2018.

Vericel's Acquisitions history runs 6 years deep, the most recent figure standing at $13.9 million for Q3 2019.

  • In Q3 2019, Acquisitions fell 68.75% year-over-year to $13.9 million; the TTM figure through Sep 2019 stood at $90.8 million (up 105.36% YoY), while the FY2014 annual figure was $1.4 million, changed N/A from the prior year.
  • Acquisitions came in at $13.9 million for Q3 2019 at Vericel, down from $21.7 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $44.5 million in Q3 2018 to a low of -$2.3 million in Q4 2015.
  • A 5-year average of $6.1 million and a median of $353000.0 in 2015 frame the typical range for Acquisitions.
  • Across the five-year window, Acquisitions slumped 213.75% in 2017 and soared 16393.04% in 2018, its largest moves.
  • Vericel's Acquisitions stood at -$2.3 million in 2015, then surged by 43.61% to -$1.3 million in 2016, then surged by 79.22% to -$273000.0 in 2017, then jumped by 16393.04% to $44.5 million in 2018, then plunged by 68.75% to $13.9 million in 2019.
  • According to Business Quant data, Acquisitions over the past three periods registered $13.9 million, $21.7 million, and $10.7 million for Q3 2019, Q2 2019, and Q1 2019 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Acquisitions (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Vericel 1.69 Bn 1.55 Bn 49.27 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2019 13.90 Mn
Jun 30, 2019 21.72 Mn
Mar 31, 2019 10.69 Mn
Sep 30, 2018 44.48 Mn
Sep 30, 2017 -273,000.00
Jun 30, 2017 203,000.00
Mar 31, 2017 70,000.00
Dec 31, 2016 -1.31 Mn
Sep 30, 2016 240,000.00
Jun 30, 2016 1.06 Mn
Mar 31, 2016 13,000.00
Dec 31, 2015 -2.33 Mn
Sep 30, 2015 775,000.00
Jun 30, 2015 1.20 Mn
Mar 31, 2015 353,000.00
Sep 30, 2014 2.50 Mn
Jun 30, 2014 -1.05 Mn